SAN DIEGO, Aug. 18, 2023 /PRNewswire/ — Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, has announced they have received written response from the U.S. Food and Drug Administration (FDA) related to their End-of-Phase 2 briefing package for AR882, its lead drug…